NYSE$CC

The Chemours · Q1 2020 earnings

Q1 2020 earnings · · Investor relations

Briefing

Chemours' Q1 2020 results reflected solid performance amidst early COVID-19 impacts, with strong balance sheet and liquidity preserved through cost reduction measures.

Chemours reported Q1 2020 net sales of $1.3 billion and net income of $100 million, or $0.61 per diluted share. Adjusted Net Income was $118 million, with Adjusted EPS of $0.71. The company enacted measures to protect employees and reduce costs by $160 million, while also reducing FY 2020 CAPEX by $125 million. Due to demand uncertainty, the company withdrew its FY 2020 guidance.

  • Net sales reached $1.3 billion.
  • Net income was $100 million, with an EPS of $0.61.
  • Adjusted EPS was $0.71, an increase of 13% year-over-year.
  • The company is reducing FY 2020 costs by $160 million and CAPEX by $125 million.

Headline financials

Total Revenue

$1.31B

Previous: $1.38B-5.2%
EPS (adj)

$0.71

Previous: $0.63+12.7%
Capital Expenditures

-$106M

Previous: -$133M+20.3%
Free Cash Flow

-$6M

Previous: -$39M+84.6%
Net Income

$100M

Previous: $94M+6.4%
Operating Income

$138M

Previous: $110M+25.5%
Gross Profit

$298M

Previous: $296M+0.7%
Cash & Equivalents

$714M

Previous: $697M+2.4%
Total Assets

$6.95B

Previous: $7.33B-5.1%
Stock-Based Comp

$8M

Previous: $8M+0.0%

Revenue & EPS history

Chemours · Revenue · Quarterly

$1.31B

Q1 2020-5.2%vs Q1 2019
Beat estimate in 14 of 16 quarters(88%)
ActualEstimate

Forward guidance

Due to the uncertainty created by the COVID-19 pandemic, Chemours is withdrawing its full-year 2020 guidance but is taking steps to manage the current conditions.

Tailwinds

  • Implementing protocols to safeguard employee health and well-being.
  • Reducing FY 2020 costs by reducing overhead.
  • Reducing FY 2020 costs by reducing discretionary spend.
  • Reducing FY 2020 costs by reducing CAPEX.
  • Engaging the Chemours team to serve customers.

Headwinds

  • Uncertainty created by the pandemic.
  • Withdrawal of full-year 2020 guidance.
  • Potential limitations on employee travel.
  • Possible adverse effects on personnel health and welfare.
  • Potential disruptions in supply chains.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2020

Historical avgQ1 2020

+1.4%

Avg return

Earnings day

+2.4%

Avg return

5 days after

+1.2%

Avg return

30 days after

55%

27 / 49 earnings

Positive

+24.2%

Q4 2019

Best reaction

-23.0%

Q2 2019

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-15.7%-9.6%-26.8%
Q4 2025-16.5%-11.7%-13.3%
Q3 2025+6.8%+7.4%+8.2%
Q1 2025-9.4%-0.9%-8.1%
Q4 2024+3.9%-0.4%-12.8%
Q3 2024+11.6%+11.1%+19.4%
Q2 2024-15.0%-22.5%-19.6%
Q1 2024-6.1%-4.0%-7.6%
Q4 2023-4.1%+5.0%-0.2%
Q3 2023-0.1%+2.1%+11.7%
Q2 2023-4.8%-4.0%-14.8%
Q1 2023+6.4%+11.1%+4.4%
Q4 2022-1.7%-0.8%-10.7%
Q3 2022+1.0%-0.9%+13.5%
Q2 2022+4.0%+1.6%+4.5%
Q1 2022+17.7%+21.1%+31.7%
Q4 2021-16.8%-13.9%-26.9%
Q3 2021+8.0%+4.7%-3.0%
Q2 2021+1.9%+4.7%+6.5%
Q1 2021+4.4%+14.7%+23.0%
Q4 2020-2.6%-1.8%+7.1%
Q3 2020+2.2%+8.3%+23.0%
Q2 2020-0.3%+5.9%+12.8%
Q1 2020+12.9%+18.3%+44.4%
Q4 2019+24.2%+19.1%-33.9%
Q3 2019+13.9%+13.4%-11.1%
Q2 2019-23.0%-26.5%-25.7%
Q1 2019-1.8%-16.4%-39.4%
Q4 2018-2.6%-3.0%-2.2%
Q3 2018+4.1%+2.9%-13.7%
Q2 2018+4.9%+6.7%-2.8%
Q1 2018+4.5%+4.4%+1.7%
Q4 2017+2.7%+2.5%+4.5%
Q3 2017-8.4%-10.5%-9.0%
Q2 2017-1.6%+3.8%+4.3%
Q1 2017-1.0%+2.4%-0.7%
Q4 2016-0.5%+3.1%+8.4%
Q3 2016+12.7%+21.1%+52.3%
Q2 2016+13.2%+25.8%+49.6%
Q1 2015-3.1%
Q1 2016+9.6%
Q1 2014+2.3%
Q4 2013+2.3%
Q4 2015+14.3%
Q3 2014-17.2%
Q3 2015-17.2%
Q4 2014+16.3%
Q2 2014+16.3%
Q2 2015+16.3%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro